https://stockhub.co/index.php?action=history&feed=atom&title=Citius_Pharmaceuticals%2C_Inc.Citius Pharmaceuticals, Inc. - Revision history2026-05-28T11:20:29ZRevision history for this page on the wikiMediaWiki 1.43.5https://stockhub.co/index.php?title=Citius_Pharmaceuticals,_Inc.&diff=58296&oldid=prev>Nick: Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by s..."2022-09-01T04:15:53Z<p>Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by s..."</p>
<p><b>New page</b></p><div>== Summary<ref>Source: Yahoo Finance.</ref> ==<br />
<br />
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.<br />
<br />
== References and notes == <br />
[[Category:Thesis]]<br />
__INDEX__</div>>Nick